Early drug discovery and development corresponds to be one of the most vital areas for pharmaceutical and biopharmaceutical industry. While the pharmaceutical industry looks for enhanced and innovative solutions, it becomes increasingly important to accurately model the desired biological effect of drug in animals in order to predict treatment outcomes and prevent adverse reactions in patients. With efficacy and safety being the cornerstone, it becomes imperative to conduct effective pre-clinical studies to identify promising drug candidates while ensuring potentially toxic and unsafe drugs are filtered out at early stages.
At VIMTA, we offer a comprehensive range of preclinical services, both for small and large molecules, based on current global regulatory guidelines. With a dedicated multi-disciplinary team in Pharmacology, DMPK, Safety Pharmacology, Toxicology and Bio-analysis, we are a one-stop solution for all your drug discovery and development research needs. We provide critical pre-clinical research data and innovative solutions through conduct of right studies at right time using proven experimental designs, stringent regulatory and quality compliance and complete value chain integration.
Our state of the art facility is OECD GLP certified and AAALAC accredited, thereby enabling acceptability of data by global regulatory agencies. Our barrier controlled vivarium is LEED Gold certified by Indian Green Building Council. It has
These are designed as per the International guidelines governing the care and use of laboratory animals. We are one of the few CROs with non-rodent facilities and are approved for mini pigs and canines as test systems.
Our test facility is modular, with integrated analytical, bio-analytical and pathology labs.
We offer a comprehensive range of services for
We have more than two decades of experience in facilitating selection of right drug candidate using in-silico, in-vitro and in-vivo models; and offer multi therapeutic efficacy models and early ADMET screening for lead identification and optimization. The data generated can be presented in Electronic Common Technical Document (eCTD) and Standard for the Exchange of Non clinical data (SEND), which enables fast track review process for regulatory submissions.
At VIMTA, we have also been supporting the needs of our customers for generic drug development and offer complete range of services in accordance with the regulatory guidelines. We offer services for